Approval · Notice of Compliance 25504 · 2021
ENBREL: Notice of Compliance 25504
Issued March 19, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25504
- Date
- March 19, 2021
- Company
- Immunex CorporationThousand Oaks, California, United States
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the product monographm
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ENBREL | Not yet assigned | — |
Medicinal ingredients
- ETANERCEPT 50 MG per ML
- ETANERCEPT 50 MG per SYR
- ETANERCEPT 25 MG per VIAL